Lariam (Mefloquine) Class Action Lawsuit
The law firms of Kozyak Tropin & Throckmorton, LLP , Moore and Lee, LLP and Rubinstein Law have filed a class action lawsuit in the Northern District of California federal court against the manufacturer of the malaria prevention drug Lariam, the brand name for generic mefloquine. The lawsuit is based on the manufacturer’s failure to warn the U.S. military and its service members of the substantial and irreversible dangers of this drug and its crippling side effects.
What Do We Know About Mefloquine Toxicity?
Defendants marketed and sold Lariam to the U.S. military for service members deployed to foreign countries for the prevention of malaria. The military then ordered service members to take Lariam prior to deployment and while stationed overseas,
Defendants failed to warn the military, its physicians and its service members about the true nature and prevalence of the severe and irreversible effects associated with the drug. In fact, they misrepresented that the incidence of neuropsychiatric effects was rare and that the symptoms were mild. Defendants also failed to warn patients and prescribers about the nature and extent of the severe and irreversible effects associated with the drug.
Mefloquine toxicity is typically associated with a collection of significant neurological and psychiatric symptoms affecting balance, vision, hearing, memory, dreams, mood and behavior. The presentation of permanent neurological damage, including vertigo, balance disorders and visual disturbance, in the absence of a severe initiating traumatic incident, can further aid in distinguishing mefloquine toxicity from other causes of mental and physical illnesses. Accordingly, appropriate and adequate diagnostic testing is needed to distinguish mefloquine toxicity from other forms of illness.